BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 33479617)

  • 1. Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
    Baillache DJ; Unciti-Broceta A
    RSC Med Chem; 2020 Oct; 11(10):1112-1135. PubMed ID: 33479617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazolo[3,4-d]pyrimidine scaffold: A review on synthetic approaches and EGFR and VEGFR inhibitory activities.
    Kassab AE
    Arch Pharm (Weinheim); 2023 Jan; 356(1):e2200424. PubMed ID: 36192144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.
    Musumeci F; Sanna M; Greco C; Giacchello I; Fallacara AL; Amato R; Schenone S
    Expert Opin Ther Pat; 2017 Dec; 27(12):1305-1318. PubMed ID: 28705083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
    Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
    Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical and biological versatility of pyrazolo[3,4-
    Trentini A; Hanau S; Manfrinato MC; Cacciari B
    Future Med Chem; 2023 Dec; 15(23):2143-2148. PubMed ID: 37933597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold.
    Zhang Y; Wen D; Shen J; Tian L; Zhu Y; Zhang J; Zhao L; Ding S; Liu J; Chen Y
    Curr Top Med Chem; 2023; 23(12):1043-1064. PubMed ID: 36852801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An insight on synthetic and medicinal aspects of pyrazolo[1,5-a]pyrimidine scaffold.
    Cherukupalli S; Karpoormath R; Chandrasekaran B; Hampannavar GA; Thapliyal N; Palakollu VN
    Eur J Med Chem; 2017 Jan; 126():298-352. PubMed ID: 27894044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.
    Li W; Zhang J; Wang M; Dong R; Zhou X; Zheng X; Sun L
    Curr Top Med Chem; 2022 Mar; 22(4):284-304. PubMed ID: 35021973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New advances in synthesis and clinical aspects of pyrazolo[3,4-d]pyrimidine scaffolds.
    Abdellatif KRA; Bakr RB
    Bioorg Chem; 2018 Aug; 78():341-357. PubMed ID: 29627655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
    Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent green approaches for the synthesis of pyrazolo[3,4-d]pyrimidines: A mini review.
    Maher M; Zaher AF; Mahmoud Z; Kassab AE
    Arch Pharm (Weinheim); 2022 Jun; 355(6):e2100470. PubMed ID: 35244962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-
    Greco C; Catania R; Balacco DL; Taresco V; Musumeci F; Alexander C; Huett A; Schenone S
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33207806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
    Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
    Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino)pyrazolo[3,4-d]pyrimidines.
    Traxler P; Bold G; Frei J; Lang M; Lydon N; Mett H; Buchdunger E; Meyer T; Mueller M; Furet P
    J Med Chem; 1997 Oct; 40(22):3601-16. PubMed ID: 9357527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
    Bakr RB; Mehany ABM; Abdellatif KRA
    Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Characterization, Antimicrobial Activity and Anticancer of Some New Pyrazolo[1,5-a]pyrimidines and Pyrazolo[5,1-c]1,2,4-triazines.
    Hosny MA; Zaki YH; Mokbel WA; Abdelhamid AO
    Med Chem; 2020; 16(6):750-760. PubMed ID: 31218963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
    Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis, Characterization, Antitubercular and Anti-Inflammatory Activity of New Pyrazolo[3,4-d]Pyrimidines.
    Kulkarni R; Kompalli K; Gaddam N; Mangannavar CV; Darna B; Garlapati A; Kumar D; Machha B
    Comb Chem High Throughput Screen; 2021; 24(8):1300-1308. PubMed ID: 32957875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Synthesis of 2-(1-Alkylaminoalkyl)pyrazolo[1,5-a]pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors.
    Yamaguchi-Sasaki T; Tamura Y; Ogata Y; Kawaguchi T; Kurosaka J; Sugaya Y; Iwakiri K; Busujima T; Takahashi R; Ueda-Yonemoto N; Tanigawa E; Abe-Kumasaka T; Sugiyama H; Kanuma K
    Chem Pharm Bull (Tokyo); 2020; 68(4):345-362. PubMed ID: 32238652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.